Research ExplorerPublicationsEfficacy, safety, and tolerability of albendazole and iverme...

Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial

Standard

Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial. / Zoleko-Manego, Rella; Kreuzmair, Ruth; Veletzky, Luzia; Ndzebe-Ndoumba, Wilfrid; Ekoka Mbassi, Dorothea; Okwu, Dearie G; Dimessa-Mbadinga-Weyat, Lia B; Houtsa-Temgoua, Roselyne D; Mischlinger, Johannes; McCall, Matthew B B; Kresmner, Peter G; Agnandji, Selidji T; Lell, Betrand; Adegnika, Ayôla A; Mombo-Ngoma, Ghyslain; Ramharter, Michael.

In: PLOS NEGLECT TROP D, Vol. 17, No. 8, 08.2023, p. e0011584.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Zoleko-Manego, R, Kreuzmair, R, Veletzky, L, Ndzebe-Ndoumba, W, Ekoka Mbassi, D, Okwu, DG, Dimessa-Mbadinga-Weyat, LB, Houtsa-Temgoua, RD, Mischlinger, J, McCall, MBB, Kresmner, PG, Agnandji, ST, Lell, B, Adegnika, AA, Mombo-Ngoma, G & Ramharter, M 2023, 'Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial', PLOS NEGLECT TROP D, vol. 17, no. 8, pp. e0011584. https://doi.org/10.1371/journal.pntd.0011584

APA

Zoleko-Manego, R., Kreuzmair, R., Veletzky, L., Ndzebe-Ndoumba, W., Ekoka Mbassi, D., Okwu, D. G., Dimessa-Mbadinga-Weyat, L. B., Houtsa-Temgoua, R. D., Mischlinger, J., McCall, M. B. B., Kresmner, P. G., Agnandji, S. T., Lell, B., Adegnika, A. A., Mombo-Ngoma, G., & Ramharter, M. (2023). Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial. PLOS NEGLECT TROP D, 17(8), e0011584. https://doi.org/10.1371/journal.pntd.0011584

Vancouver

Zoleko-Manego R, Kreuzmair R, Veletzky L, Ndzebe-Ndoumba W, Ekoka Mbassi D, Okwu DG et al. Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial. PLOS NEGLECT TROP D. 2023 Aug;17(8):e0011584. https://doi.org/10.1371/journal.pntd.0011584

Bibtex

@article{b372bb810d1448bd82f2decea00da583,
title = "Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial",
abstract = "BACKGROUND: There is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assessed albendazole and ivermectin based treatment regimens to reduce Loa loa microfilaraemia in Gabon.METHODS: Eligible adult patients with L. loa microfilaraemia between 5,000 and 50,000 microfilariae/ml were randomized to either a control or one of three intervention groups (1:2:2:2 allocation ratio) consisting of three-week twice daily 400mg oral albendazole followed by 1) no treatment, 2) two further weeks of twice daily 400mg albendazole, or 3) a single dose of ivermectin in this open label randomized assessor blinded controlled clinical trial. The primary outcome was the proportion of participants with L. loa microfilaraemia ≤ 100 mf/ml at Day 168.RESULTS: In the efficacy-population of 42 patients 0 (0%; control group), 1 (9%; 3-week albendazole), 5 (39%; 5-weeks albendazole) and 2 (22%; 3-week albendazole plus single dose ivermectin) participants met the primary outcome of microfilaraemia below 100/ml at day 168. A 80-90% reduction of microfilaraemia was observed in the active treatment groups.CONCLUSION: The 5-week regimen of albendazole or a 3-week regimen of albendazole followed by ivermectin were most efficacious to reduce microfilaraemia. All therapeutic regimens were well tolerated and safe.TRIAL REGISTRATION: Trial registered at the Pan-African Clinical Trials Registry: PACTR201807197019027.",
keywords = "Humans, Adult, Animals, Albendazole/adverse effects, Ivermectin/adverse effects, Gabon, Loiasis/drug therapy, Clinical Protocols, Fishes",
author = "Rella Zoleko-Manego and Ruth Kreuzmair and Luzia Veletzky and Wilfrid Ndzebe-Ndoumba and {Ekoka Mbassi}, Dorothea and Okwu, {Dearie G} and Dimessa-Mbadinga-Weyat, {Lia B} and Houtsa-Temgoua, {Roselyne D} and Johannes Mischlinger and McCall, {Matthew B B} and Kresmner, {Peter G} and Agnandji, {Selidji T} and Betrand Lell and Adegnika, {Ay{\^o}la A} and Ghyslain Mombo-Ngoma and Michael Ramharter",
note = "Copyright: {\textcopyright} 2023 Zoleko-Manego et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",
year = "2023",
month = aug,
doi = "10.1371/journal.pntd.0011584",
language = "English",
volume = "17",
pages = "e0011584",
journal = "PLOS NEGLECT TROP D",
issn = "1935-2735",
publisher = "Public Library of Science",
number = "8",

}

RIS

TY - JOUR

T1 - Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial

AU - Zoleko-Manego, Rella

AU - Kreuzmair, Ruth

AU - Veletzky, Luzia

AU - Ndzebe-Ndoumba, Wilfrid

AU - Ekoka Mbassi, Dorothea

AU - Okwu, Dearie G

AU - Dimessa-Mbadinga-Weyat, Lia B

AU - Houtsa-Temgoua, Roselyne D

AU - Mischlinger, Johannes

AU - McCall, Matthew B B

AU - Kresmner, Peter G

AU - Agnandji, Selidji T

AU - Lell, Betrand

AU - Adegnika, Ayôla A

AU - Mombo-Ngoma, Ghyslain

AU - Ramharter, Michael

N1 - Copyright: © 2023 Zoleko-Manego et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2023/8

Y1 - 2023/8

N2 - BACKGROUND: There is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assessed albendazole and ivermectin based treatment regimens to reduce Loa loa microfilaraemia in Gabon.METHODS: Eligible adult patients with L. loa microfilaraemia between 5,000 and 50,000 microfilariae/ml were randomized to either a control or one of three intervention groups (1:2:2:2 allocation ratio) consisting of three-week twice daily 400mg oral albendazole followed by 1) no treatment, 2) two further weeks of twice daily 400mg albendazole, or 3) a single dose of ivermectin in this open label randomized assessor blinded controlled clinical trial. The primary outcome was the proportion of participants with L. loa microfilaraemia ≤ 100 mf/ml at Day 168.RESULTS: In the efficacy-population of 42 patients 0 (0%; control group), 1 (9%; 3-week albendazole), 5 (39%; 5-weeks albendazole) and 2 (22%; 3-week albendazole plus single dose ivermectin) participants met the primary outcome of microfilaraemia below 100/ml at day 168. A 80-90% reduction of microfilaraemia was observed in the active treatment groups.CONCLUSION: The 5-week regimen of albendazole or a 3-week regimen of albendazole followed by ivermectin were most efficacious to reduce microfilaraemia. All therapeutic regimens were well tolerated and safe.TRIAL REGISTRATION: Trial registered at the Pan-African Clinical Trials Registry: PACTR201807197019027.

AB - BACKGROUND: There is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assessed albendazole and ivermectin based treatment regimens to reduce Loa loa microfilaraemia in Gabon.METHODS: Eligible adult patients with L. loa microfilaraemia between 5,000 and 50,000 microfilariae/ml were randomized to either a control or one of three intervention groups (1:2:2:2 allocation ratio) consisting of three-week twice daily 400mg oral albendazole followed by 1) no treatment, 2) two further weeks of twice daily 400mg albendazole, or 3) a single dose of ivermectin in this open label randomized assessor blinded controlled clinical trial. The primary outcome was the proportion of participants with L. loa microfilaraemia ≤ 100 mf/ml at Day 168.RESULTS: In the efficacy-population of 42 patients 0 (0%; control group), 1 (9%; 3-week albendazole), 5 (39%; 5-weeks albendazole) and 2 (22%; 3-week albendazole plus single dose ivermectin) participants met the primary outcome of microfilaraemia below 100/ml at day 168. A 80-90% reduction of microfilaraemia was observed in the active treatment groups.CONCLUSION: The 5-week regimen of albendazole or a 3-week regimen of albendazole followed by ivermectin were most efficacious to reduce microfilaraemia. All therapeutic regimens were well tolerated and safe.TRIAL REGISTRATION: Trial registered at the Pan-African Clinical Trials Registry: PACTR201807197019027.

KW - Humans

KW - Adult

KW - Animals

KW - Albendazole/adverse effects

KW - Ivermectin/adverse effects

KW - Gabon

KW - Loiasis/drug therapy

KW - Clinical Protocols

KW - Fishes

U2 - 10.1371/journal.pntd.0011584

DO - 10.1371/journal.pntd.0011584

M3 - SCORING: Journal article

C2 - 37639396

VL - 17

SP - e0011584

JO - PLOS NEGLECT TROP D

JF - PLOS NEGLECT TROP D

SN - 1935-2735

IS - 8

ER -